

3 March 2026

LEADING SINGAPORE HOSPITAL NOW ORDERING CXBLADDER

DUNEDIN, New Zealand – Cancer diagnostics company Pacific Edge (NZX, ASX: PEB) today announces its Dunedin laboratory has signed a service agreement with Singapore General Hospital (SGH), an important milestone in the company’s strategy to drive the adoption of its tests in the Asia Pacific.

Physicians and clinicians at SGH may now order Cxbladder Triage or Triage Plus for the evaluation of patients presenting with hematuria, and Cxbladder Monitor for the surveillance of bladder cancer recurrence.

SGH is government funded, and the largest and oldest hospital in Singapore, serving a population of more than 1 million patients annually¹.

SGH is committed to reducing unnecessary or unwanted cystoscopies, and the initial clinical implementation will focus on offering microhematuria patients Triage Plus and offering Monitor to lower risk NMIBC² patients on surveillance as an alternative to reduce the frequency of cystoscopy. Patients may be required to pay for the tests, so will be given the choice of a cystoscopy or Cxbladder.

While initial monthly volumes are expected to be modest as clinical teams become familiar with Cxbladder testing, Pacific Edge is seeking to leverage this success with other regional hospitals and clinicians, given the leading role SGH plays in setting the standards for healthcare across the Asia Pacific region.

Pacific Edge Chief Executive Dr Peter Meintjes said: “We’re delighted to be supporting Singapore General Hospital as they implement Cxbladder testing for their hematuria and NMIBC patients.

“The clinical benefits of our non-invasive genomic urine tests are well established with the inclusion of Cxbladder Triage in the AUA/SUFU Microhematuria Guideline³ and from the real-world evidence in New Zealand and the Kaiser Permanente system in the US. The tests demonstrated economic benefits⁴ are meanwhile particularly important in public or other capitated systems. Cxbladder will reduce the volume of unnecessary cystoscopies, help clinical teams streamline resource utilization, and improve day-to-day patient care for those patients most in need,” Dr Meintjes said.

¹ <https://www.sgh.com.sg/about-sgh/who-we-are>

² NMIBC is non-muscle invasive bladder cancer

³ Barocas DA, Lotan Y, Matulewicz RS, Raman JD, Westerman ME, Kirkby E, Pak L, Souter L. Updates to Microhematuria: AUA/SUFU Guideline (2025). *J Urol*. 0(0). doi: 10.1097/JU.0000000000004490

Barocas et al. (2025). Updates to Microhematuria: AUA/SUFU Guideline (2025). *The Journal of urology*, 213(5), 547–557. <https://doi.org/10.1097/JU.0000000000004490>.

⁴ Tyson et al (2024) Budgetary Impact of Including the Urinary Genomic Marker Cxbladder Detect in the Evaluation of Microhematuria Patients - PubMed (PMID: 37914255)

“We are working closely with SGH, recognizing the important role the hospital and its clinicians play in driving clinical practice change across the country and the entire Asia Pacific region.”

Triage Plus is the next generation test from Pacific Edge – a multi-modal (RNA and DNA) urine-based genomic test with substantially improved performance characteristics when contrasted with Pacific Edge’s first-generation tests, Triage and Detect for hematuria evaluation.

With the recent publication of the DRIVE study⁵ in the Journal of Urologic Oncology providing an independent clinical validation, Triage Plus builds on the performance of Cxbladder Triage, a test now included in the AUA Guideline supported with ‘Grade A’ evidence from the first ever randomized controlled trial of a urine biomarker (STRATA⁶). Triage Plus is available throughout the Asia Pacific region to Australian, New Zealand and Southeast Asian customers.

Released for and on behalf of Pacific Edge by Grant Gibson, Chief Financial Officer.

Pacific Edge: www.pacifiedgedx.com

Pacific Edge Limited (NZX/ ASX: PEB) is a global cancer diagnostics company leading the way in the development and commercialization of bladder cancer diagnostic and prognostic tests for patients presenting with hematuria or surveillance of recurrent disease. Headquartered in Dunedin, New Zealand, the company provides its suite of Cxbladder tests globally through its wholly owned, and CLIA certified, laboratories in New Zealand and the USA.

Cxbladder: www.cxbladder.com

Cxbladder is a suite of non-invasive genomic urine tests optimized for the risk stratification of urothelial cancer in patients presenting with microhematuria and those being monitored for recurrent disease. The tests help improve the overall patient experience, while prioritizing time and clinical resources to optimize practice workflow and improve efficiency.

Supported by over 20 years of research, Cxbladder’s evidence portfolio extends to more than 25 peer reviewed publications, and Cxbladder Triage is now included in the American Urological Association’s Microhematuria Guideline. To drive increased adoption and improved patient health outcomes, Cxbladder is the focal point of numerous ongoing and planned studies designed to generate further clinical utility evidence.

Cxbladder is available in the US, Australasia, and Israel and in markets throughout Asia and South America. In the US, the test has been used by over 5,000 urologists who have ordered

⁵ Savage et al. (2025). Diagnostic performance of Cxbladder Triage Plus for the identification and stratification of patients at risk for urothelial carcinoma: The multicenter, prospective, observational DRIVE study. *Urologic oncology*, S1078-1439(25)00405-3. Advance online publication. <https://doi.org/10.1016/j.urolonc.2025.10.008>

⁶ Lotan et al. (2024). A Multicenter Prospective Randomized Controlled Trial Comparing Cxbladder Triage to Cystoscopy in Patients With Microhematuria. The Safe Testing of Risk for Asymptomatic Microhematuria Trial. *The Journal of Urology* Vol 212(1) 41-51.

more than 130,000 tests. In New Zealand, Cxbladder is accessible to around 70% of the population via public healthcare and all residents have the option of buying the test online.